Dapagliflozin
Dapagliflozin has been studied in 510 papers since 2012: 107 trials and 135 observational studies in people, 107 in animals, 18 in cells, 111 reviews; 355 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.
InterventionSGLT2 inhibitorsApproved 2012
510 papers study it23 more mention it765 findingsUpdated
123 new papers in 30 daysSee all 518 papers on dapagliflozin
At a glance
Human trials report fewer heart failure events with dapagliflozin, while one trial finds no clear effect on cellular senescence. One group reports improved fly healthspan, and independent labs reproduce lower oxidative stress in mice and lower HbA1c in humans, although a human trial finds no clear HbA1c effect. Some human papers declare ties to developer AstraZeneca.
765 findings in 285 papers from 2012 to 2026, 108 of them since May 2026
Independent labs found the same change in cells, mice and people. 204 independent labs in 37 countries; 406 trials, 124 about aging, 101 with no results posted.
“only high-dose dapagliflozin (10 mg/day) significantly reduced the occurrence of delirium and depression”
55 of its findings point the other way.
- 204 independent labs in 37 countries
- 55 findings against
- 406 trials, 124 about aging, 101 with no results posted
- Funders: National Natural Science Foundation of China and others
- 98 of 730 findings with company ties
- 162 of 406 trials sponsored by its developers
- Human trial105
- Humans134
- Animals98
- Model organisms2
- Cells17
- In silico10
Studies in people
See all 88 studies of dapagliflozin in people88 studies gave dapagliflozin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves chronic eGFR slopeBetween-group difference 1.7 mL/min/1.73 m2 (95% CI 0.1–3.3); p = 0.03 no change: Has no effect on adverse event rates | Randomized trial2 weeks to 12 months | 424 peopleBoth53 ± 14 yearsMidlife adults; Heart transplant recipients | Circulation, Nov 8, 2026 |
up: Increases HDL cholesterol down: Decreases rectus femoris cross-sectional area7.12 to 6.65 cm2 | Treated cohort | 37 peopleMenAdults; median age 60 yearsOlder adults; HIV and chronic kidney disease | Preprints.org, Nov 6, 2026 |
down: Decreases NT-proBNP−34.2% vs. −25.0%; P = 0.003 | Randomized trial72 hours | 108 peopleadultsHospitalized acute heart failure | Clinical pharmacology and therapeutics, Nov 3, 2026 |
down: Decreases hepatic steatosisCAP 310.2 to 287.0 dB/m down: Decreases liver stiffness measurement−0.46 kPa | Treated cohort25 weeks | 27 people18–70 yearsMASLD | Endocrinology, diabetes & metabolism, Nov 1, 2026 |
no change: Has no effect on left ventricular mass indexAdjusted mean difference -3.7 g/m2; 95% CI -11.2 to 3.8 down: Decreases left ventricular mass indexAdjusted mean difference −9.2 g/m2; P=0.035 | Randomized trial6 months | 220 peopleBoth65 yrsOlder adults; kidney failure receiving maintenance hemodialysis and left ventricular hypertrophy | ESC Congress 2026 abstract, Oct 26, 2026 |
What did studies of dapagliflozin find?
447Studies of dapagliflozin measured 447 outcomes, among them HbA1c, oxidative stress and ROS signaling and inflammation.
HbA1c
downin humans13no changein humans3
16 studies
HbA1c
downin humans13no changein humans3
Dapagliflozin showed no clear effect on HbA1c in humans (Kidney transplant recipients with post-transplant diabetes mellitus; versus standard care).
“whereas HbA1c and tacrolimus trough concentrations were similar.”
Human trialKidney transplant recipients with post-transplant diabetes mellitus; versus standard care10 mg daily54 weeks
Diabetes research and clinical practice
Dapagliflozin decreases HbA1c in humans (as an adjunct to insulin).
“Similarly, Group B demonstrated reductions of 23.6% in FBG, 25.1% in 2hPBG, and 24.9% in HbA1c. FBG, 2hPBG and HbA1c reductions were significantly greater in Group B than in Group A, indicating superior blood glucose index control.”
Human trialas an adjunct to insulin3 months post-dischargen = 90
Clinics (Sao Paulo, Brazil)
Dapagliflozin decreases HbA1c in humans (adjunct to insulin in type 2 diabetes) (24.9% vs. 10.3%).
“Reductions in Group B versus Group A were: HbA1c (24.9%vs. 10.3%)”
Human trialadjunct to insulin in type 2 diabetes3 monthsn = 86
Clinics (Sao Paulo, Brazil)
Dapagliflozin decreases HbA1c in humans (added to semaglutide, Period 2 (weeks 26 to 52), vs placebo) (-0.46% HbA1c vs placebo).
“In Period 2, HbA1c was further reduced by 0.46% (95% CI -0.78, -0.14; p=0.003) by dapagliflozin vs placebo”
Human trialadded to semaglutide, Period 2 (weeks 26 to 52), vs placebooral10 mg daily26 weeksn = 36
ADA Scientific Sessions 2026 abstract
Dapagliflozin showed no clear effect on HbA1c in humans (fell by 0.8% in both groups).
“HbA1c fell by 0.8% in both groups with no between-group difference (p = 0.887), although fasting plasma glucose, fasting insulin, and HOMA2 dropped significantly in dapagliflozin arm..”
Human trial12 weeksn = 98
Cardiovascular diabetology
Dapagliflozin showed no clear effect on HbA1c in humans (type 2 diabetes) (between-group p = 0.887).
“glycemic control improved similarly in both groups (median [IQR] HbA1c change: -0.78 [0.11]% vs. -0.80 [0.10]%; between-group p = 0.887).”
Human trialtype 2 diabetes12 weeksn = 96
Cardiovascular diabetology
Dapagliflozin decreases HbA1c in humans (type 2 diabetes; compared with placebo) (-0.52 vs. 0.11; p = 0.012).
“dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015), and HbA1c (-0.52 vs. 0.11, p = 0.012).”
Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56
Obesity (Silver Spring, Md.)
Dapagliflozin decreases HbA1c in humans (newly diagnosed T2DM patients with evidence of micro- or macro-albuminuria) (from 9.04% to 7.31% (P < 0.001)).
“Glycemic control was rapidly achieved, with a mean HbA1c drop from 9.04% to 7.31% (P < 0.001).”
Human trialnewly diagnosed T2DM patients with evidence of micro- or macro-albuminuria10 mg/day3 monthsn = 133
Diabetology & metabolic syndrome
Dapagliflozin showed no clear effect on HbA1c in humans.
“This indicates that HbA1c levels decreased significantly throughout the treatment period regardless of the therapeutic regimen employed, yet no differences were observed between the three treatment groups in their efficacy or rate of HbA1c reduction.”
Human trialn = 81
Journal of diabetes research
Dapagliflozin decreases HbA1c in humans.
“Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations.”
Human trial2-4 yearsn = 6
The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance
Pediatric diabetes
All 18Fewer
Oxidative stress and ROS signaling
downin rats7downin mice3downin human cells2downin humans2+2
16 studies
Oxidative stress and ROS signaling
downin rats7downin mice3downin human cells2downin humans2+2
Dapagliflozin decreases oxidative stress and ROS signaling in humans (mean difference: +115 ng/mL, 95% CI: 39 to 191 ng/mL, P = 0.0047).
“After treatment, MPO (mean difference: +115 ng/mL, 95% confidence interval (CI): 39 to 191 ng/mL, P = 0.0047), MMP-1 (mean difference: +306 ng/mL, 95% CI: 124 to 488 ng/mL, P = 0.0021), and MMP-9 (mean difference: +6,196 ng/mL, 95% CI: 670 to 11,721 ng/mL, P = 0.029) levels significantly decreased, whereas MMP-2 (mean difference: +723 ng/mL, 95% CI: -1,280 to 2,726 ng/mL, P = 0.46) showed no significant change”
Human trial6 monthsn = 25
Cardiology research
Dapagliflozin decreases oxidative stress and ROS signaling in humans (heart failure with reduced ejection fraction).
“oxidative stress markers including myeloperoxidase, matrix metalloproteinase-1, and matrix metalloproteinase-9 significantly improved”
Human trialheart failure with reduced ejection fraction6 months
Cardiology research
Dapagliflozin decreases oxidative stress and ROS signaling in human cells with alpelisib and fulvestrant under hyperglycemia.
“Transcriptomic analysis confirmed coordinated downregulation of oxidative stress, inflammatory, and insulin-stress pathways.”
Cellswith alpelisib and fulvestrant under hyperglycemiaiPSC-derived cardiomyocytes
ESC Congress 2026 abstract
Dapagliflozin inhibits oxidative stress and ROS signaling in rats (against DOX-related cardiotoxicity).
“Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.”
Animalsagainst DOX-related cardiotoxicityheart12 weeksmales
Immunopharmacology and immunotoxicology
Dapagliflozin decreases oxidative stress and ROS signaling in rats (isoproterenol-induced myocardial injury).
“DAPA significantly reduced ISO-induced elevations in cardiac troponin-I, creatine kinase-MB, lactate dehydrogenase, and oxidative stress markers”
Animalsisoproterenol-induced myocardial injuryheart1 mg/kg/day14 daysmales
International journal of applied & basic medical research
Dapagliflozin decreases oxidative stress and ROS signaling in cells (myocardial IRI).
“Dapa upregulates EGFR phosphorylation, suppresses NHE1 expression in myocardial tissues, modulates NCOA4-mediated ferritinophagy to enhance mitochondrial function, reduces ROS expression, and mitigates myocardial IRI.”
Cellsmyocardial IRImyocardium
Life sciences
Dapagliflozin decreases oxidative stress and ROS signaling in rats (propylthiouracil-induced hypothyroidism).
“Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect”
Animalspropylthiouracil-induced hypothyroidismlung and liver1 mg/kg/dayfive weeks
Molecular biology reports
Dapagliflozin decreases oxidative stress and ROS signaling in mice under chronic stress.
“reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”
Animalsunder chronic stress
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Dapagliflozin induces oxidative stress and ROS signaling in chickens.
“intracellular oxidative stress is confirmed by SOD and CAT assays, implicating oxidative stress as a central mediator of these abnormalities”
Animalsheart1.0-2.5 mg/mL
Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model
Journal of applied toxicology : JAT
Dapagliflozin decreases oxidative stress and ROS signaling in rats (myocardial ischemia/reperfusion injury).
“DAPA reduced oxidative stress by decreasing malondialdehyde (MDA) levels and increasing superoxide dismutase (SOD) activity.”
Animalsmyocardial ischemia/reperfusion injury1 mg/kg/day14 daysmales
Journal of cardiovascular pharmacology
All 17Fewer
Inflammation
downin rats9downin mice4downin human cells1downin humans1
15 studies
Inflammation
downin rats9downin mice4downin human cells1downin humans1
Dapagliflozin decreases inflammation in humans.
“On the other hand, white blood cells, alanine aminotransferase, ferritin, CRP, brain natriuretic peptide, urinary N-acetyl-β-D-glycosaminidase, and urinary creatinine significantly decreased after treatment.”
Human trial6 monthsn = 25
Cardiology research
Dapagliflozin decreases inflammation in mice (experimental myocardial infarction).
“Histological analyses (H&E and Masson staining) revealed attenuated inflammatory infiltration and myocardial fibrosis in DAPA-treated mice.”
Animalsexperimental myocardial infarctionheart
ESC Congress 2026 abstract
Dapagliflozin decreases inflammation in aortic stenosis rats.
“Myocardial concentration of the cytokines IL-1β, IL-6, IL-10 and TNF-α was higher in AS than Sham and AS-Dapa.”
Animalsin aortic stenosis ratsheart12 weeksmales
ESC Congress 2026 abstract
Dapagliflozin decreases inflammation in a rat model of myocardial infarction-induced heart failure.
“In vivo, DAPA suppressed myocardial STAT1 expression, alleviated inflammation, normalized macrophage polarization, and reduced cytokine and bile acid abnormalities.”
Animalsin a rat model of myocardial infarction-induced heart failuremyocardium6 mg/kg/day4 weeks
PloS one
Dapagliflozin decreases inflammation in rats (methotrexate-induced liver injury).
“suppressed inflammatory and apoptotic markers”
Animalsmethotrexate-induced liver injuryliver10 mg/kg/day10 daysfemales
International journal of molecular sciences
Dapagliflozin decreases inflammation in rats (isoproterenol-induced myocardial injury).
“DAPA also attenuated inflammatory cytokines: tumor necrosis factor-alpha and interleukin-6 (IL-6).”
Animalsisoproterenol-induced myocardial injury1 mg/kg/day14 daysmales
International journal of applied & basic medical research
Dapagliflozin decreases inflammation in diabetic db/db mice.
“Fibrosis and inflammation-associated pathways in SMC and fibroblasts, and dysfunction markers in endothelial cells, increased in diabetes and were partly reversed by DAPA.”
Animalsin diabetic db/db miceaorta6 weeks
Arteriosclerosis, thrombosis, and vascular biology
Dapagliflozin decreases inflammation in mice under chronic stress.
“reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”
Animalsunder chronic stress
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Dapagliflozin decreases inflammation in rats (myocardial ischemia/reperfusion injury).
“reduced myocardial inflammation by improving myocardial TNF-α, NF-κB, IL-1β, and IL-6.”
Animalsmyocardial ischemia/reperfusion injurymyocardium1 mg/kg/day14 daysmales
Journal of cardiovascular pharmacology
Dapagliflozin decreases inflammation in mice (HFD/STZ-induced T2DM mice).
“effectively inhibit neuroinflammation (significantly reduced levels of tumor necrosis factor-α, interleukin-1β, and interleukin-6)”
AnimalsHFD/STZ-induced T2DM mice
Toxicology and applied pharmacology
All 15Fewer
Body weight
downin humans9downin chickens1upin humans1downin rats1+2−47%
14 studies
Body weight
downin humans9downin chickens1upin humans1downin rats1+2−47%
Dapagliflozin decreases body weight in humans (as an adjunct to insulin) (-5.4% vs -3.3%).
“Group A showed reductions of 3.2% in SBP, 7.8% in DBP, 4.3% in BMI and 3.3% in BW, while Group B demonstrated significantly greater reductions (7.3% in SBP, 12.6% in DBP, 9.8% in BMI and 5.4% in BW).”
Human trialas an adjunct to insulin3 months post-dischargen = 90
Clinics (Sao Paulo, Brazil)
Dapagliflozin improves body weight in T2DM patients with MASLD.
“Improvements were also observed in glycaemic control, body weight, lipid profile, liver enzymes, ultrasonographic steatosis grading, and serum fibrosis markers.”
Human trialin T2DM patients with MASLD10 mg daily12 monthsn = 50
Diabetes research and clinical practice
Dapagliflozin decreases body weight in humans (type 2 diabetes; compared with placebo) (-3.84 vs. -1.42 kg; p = 0.015).
“dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015)”
Human trialtype 2 diabetes; compared with placebo10 mg12 monthsn = 56
Obesity (Silver Spring, Md.)
Dapagliflozin decreases body weight in obese patients with T2DM without established cardiovascular disease.
“Participants experienced statistically significant reductions in their HbA1c, fasting plasma glucose, low-density lipoprotein cholesterol, total cholesterol, body weight, BMI, WHR, BFM, and aortic PWV”
Human trialin obese patients with T2DM without established cardiovascular disease10 mg daily6 months
SAT-587 The Effects of Dapagliflozin on Diabetes Mellitus without Cardiovascular Disease
ENDO 2025 abstract
Dapagliflozin decreases body weight in humans (-4 kg).
“DAPA and MET resulted in -4kg weight loss”
Human trial1 yearn = 47
Beta-Cell Preservation with Early Oral Antidiabetic Medications in Prediabetes (PreDM)
ADA Scientific Sessions 2025 abstract
Dapagliflozin decreases body weight in humans (−1.3 kg, 95% CI −1.9 to −0.7 kg).
“We found a significant difference between the two groups in weight change (−1.3 (95% CI −1.9 to −0.7) kg).”
Human trial12 monthsn = 328
BMJ (Clinical research ed.)
Dapagliflozin decreases body weight in humans with calorie restriction (difference -1.3 (95% CI -1.9 to -0.7) kg).
“Changes in body weight (difference -1.3 (95% CI -1.9 to -0.7) kg) and homoeostasis model assessment of insulin resistance (difference -0.8, -1.1 to -0.4) were significantly greater in the dapagliflozin group”
Human trialwith calorie restriction10 mg/day12 monthsn = 328
BMJ (Clinical research ed.)
Dapagliflozin decreases body weight in humans (vs placebo) (1·5 kg (0·03-3·0)).
“Compared with placebo, bodyweight was reduced by 1·5 kg (0·03-3·0; p=0·046) with dapagliflozin”
Human trialvs placebo10 mg per day6 weeksn = 53
The lancet. Diabetes & endocrinology
Dapagliflozin is linked with lower body weight in humans.
“Dapagliflozin therapy was associated with significant improvements in body weight, BMI, and blood pressure at 6 months in both groups”
Humans6 months
Nutrients
Dapagliflozin is linked with lower body weight in humans (real-world HFrEF patients) (P < .001).
“with significant reductions in body weight and heart rate (P < .001)”
Humansreal-world HFrEF patients15.3 ± 8.3 monthsn = 155
Impact of Dapagliflozin on Heart Failure with Reduced Ejection Fraction: A Real-World Study
Journal of clinical pharmacology
All 15Fewer
Cellular senescence
downin human cells6downin mice5downin rats2no changein humans1+1
12 studies
Cellular senescence
downin human cells6downin mice5downin rats2no changein humans1+1
Dapagliflozin showed no clear effect on cellular senescence in humans.
“There were no significant changes in these markers.”
Human trial6 monthsn = 25
Cardiology research
Dapagliflozin decreases cellular senescence in high glucose-treated HK-2 cells.
“Dapagliflozin reduced the expression of renal senescence markers in both in vivo and in vitro experiments.”
Cellsin high glucose-treated HK-2 cells
Biochemical pharmacology
Dapagliflozin decreases cellular senescence in streptozotocin-induced diabetic mice.
“Dapagliflozin reduced the expression of renal senescence markers in both in vivo and in vitro experiments.”
Animalsin streptozotocin-induced diabetic micekidney
Biochemical pharmacology
Dapagliflozin decreases cellular senescence in rats (HFD/STZ/UNx-induced DKD).
“dapagliflozin (0.1 mg/kg/day) improved metabolic abnormalities and renal dysfunction and attenuated tubular senescence”
AnimalsHFD/STZ/UNx-induced DKDkidney tubule0.1 mg/kg/day
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Dapagliflozin decreases cellular senescence in TAA-induced rats.
“Mechanistically, both drugs suppressed fibrotic and senescence markers, downregulated PD-1, enhanced sirtuin-1, and mitigated oxidative stress.”
Animalsin TAA-induced ratslivermales
Advanced pharmaceutical bulletin
Dapagliflozin decreases cellular senescence in human cells under high-fat conditions.
“by which the accumulation of senescent cells in human aortic smooth muscle cells (HASMCs) was reduced under high-fat conditions”
Cellsunder high-fat conditions
Science China. Life sciences
Dapagliflozin decreases cellular senescence in ApoE-/- mice (16.4%±3.7% vs. 30.7%±2.0% (P<0.01)).
“the percentage of senescent cells within the plaques (16.4%±3.7% vs. 30.7%±2.0%, P<0.01)”
Animalsin ApoE-/- miceaorta0.1 mg kg−1 d−114 weeks
Science China. Life sciences
Dapagliflozin decreases cellular senescence in human cells (H2O2-induced senescence in HK-2 cells).
“Senescent human proximal tubular epithelial (HK-2) cells induced by H2 O2 also exhibit lower senescent markers after dapagliflozin treatment.”
CellsH2O2-induced senescence in HK-2 cells
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
Journal of cellular and molecular medicine
Dapagliflozin decreases cellular senescence in mice (natural kidney senescence in SAMP8 mice).
“inhibiting expression of senescence-related biomarkers”
Animalsnatural kidney senescence in SAMP8 micekidney4 months
SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice
Journal of cellular and molecular medicine
Dapagliflozin decreases cellular senescence in HG-induced T2D mouse model (significantly reduced senescence activity in mouse aortas).
“mouse aortas had significantly reduced levels of senescence activity and senescence-associated inflammatory factors”
Animalsin HG-induced T2D mouse modelaorta
Heliyon
All 15Fewer
Apoptosis
downin rats8downin human cells2upin human cells1downin mice1
12 studies
Apoptosis
downin rats8downin human cells2upin human cells1downin mice1
Dapagliflozin increases apoptosis in human cells (combined with doxorubicin–trastuzumab in HER2-positive breast cancer cells) (p < 0.001).
“Both canagliflozin and dapagliflozin significantly enhanced the cytotoxicity of doxorubicin–trastuzumab in HER2-positive breast cancer cells, as evidenced by reduced proliferation and increased apoptotic activity (p < 0.001).”
Cellscombined with doxorubicin–trastuzumab in HER2-positive breast cancer cellsHER2-positive breast cancer cells (BT-474, SKBR3)5 μM
ESC Congress 2026 abstract
Dapagliflozin inhibits apoptosis in rats (against DOX-related cardiotoxicity).
“Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.”
Animalsagainst DOX-related cardiotoxicityheart12 weeksmales
Immunopharmacology and immunotoxicology
Dapagliflozin decreases apoptosis in rats (methotrexate-induced liver injury).
“suppressed inflammatory and apoptotic markers”
Animalsmethotrexate-induced liver injuryliver10 mg/kg/day10 daysfemales
International journal of molecular sciences
Dapagliflozin inhibits apoptosis in rats (isoproterenol-induced myocardial injury).
“DAPA downregulated the pro-apoptotic protein (Bax) expression and upregulated the anti-apoptotic protein (Bcl2) levels in the heart.”
Animalsisoproterenol-induced myocardial injuryheart1 mg/kg/day14 daysmales
International journal of applied & basic medical research
Dapagliflozin prevents apoptosis in rats (propylthiouracil-induced hypothyroidism).
“Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect”
Animalspropylthiouracil-induced hypothyroidismliver1 mg/kg/dayfive weeks
Molecular biology reports
Dapagliflozin inhibits apoptosis in mice under chronic stress.
“reduced inflammation and oxidative stress and inhibited apoptosis in the aorta and HUVECs”
Animalsunder chronic stress
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Dapagliflozin decreases apoptosis in rats (cisplatin-treated rats).
“DAPA attenuated oxidative stress, inflammation, and apoptotic pathways.”
Animalscisplatin-treated ratsbrain1 mg/kg/day4 weeksmalesn = 40
Neurotoxicology
Dapagliflozin decreases apoptosis in rats (doxorubicin-induced apoptosis).
“Further evidence of DAPA's anti-apoptotic effects was attributed to a decrease in the immunohistochemical expression of total caspase-3”
Animalsdoxorubicin-induced apoptosis2 mg/kg28 consecutive days
Neurochemical research
Dapagliflozin decreases apoptosis in rats after coronary microembolization.
“Heart dysfunction and tissue damage caused by CME can be alleviated by pre-treatment with DAPA, which also reduces myocardial inflammation and apoptosis.”
Animalsafter coronary microembolizationmyocardium
Frontiers in bioscience (Landmark edition)
Dapagliflozin protects against apoptosis in rats (lipopolysaccharide-induced acute lung injury).
“DPG exhibited protective effects against inflammation, oxidative stress, and subsequent apoptosis”
Animalslipopolysaccharide-induced acute lung injurylung10 mg/kgfive consecutive days
Molecular biology reports
All 12Fewer
Left ventricular ejection fraction
upin humans7no changein humans3upin rats1
11 studies
Left ventricular ejection fraction
upin humans7no changein humans3upin rats1
Dapagliflozin showed no clear effect on left ventricular ejection fraction in humans (at 3 months, compared with placebo) (dapagliflozin +5.4±10.1%; placebo +3.6±14.2%).
“LVEF improved significantly in both groups without a between-group difference”
Human trialat 3 months, compared with placeboleft ventricle20 mg loading dose before wire crossing, then 10 mg daily3 months
Dapagliflozin showed no clear reduction in heart attack size
ESC Congress 2026 abstract
Dapagliflozin showed no clear effect on left ventricular ejection fraction in humans (at 12 weeks post-PCI, compared with placebo).
“LVEF did not differ between groups at 12 weeks post-PCI”
Human trialat 12 weeks post-PCI, compared with placeboheart20 mg loading dose followed by 10 mg daily12 weeks
Dapagliflozin improved blood-cell resistance to energy stress
ESC Congress 2026 abstract
Dapagliflozin improves left ventricular ejection fraction in humans (type 2 diabetes mellitus) (+0.8%, p = .003).
“Left ventricular ejection fraction (LVEF) improved modestly (+0.8%, p = .003)”
Human trialtype 2 diabetes mellitus3 monthsn = 700
British journal of clinical pharmacology
Dapagliflozin increases left ventricular ejection fraction in humans (STEMI undergoing primary PCI; baseline LVEF ≤40%; without diabetes or heart failure) (41.1 ± 5.5 vs. 38.1 ± 6.9; P = 0.037).
“a significant increase in LVEF in dapagliflozin-treated patients with baseline LVEF ≤40% compared with the placebo group”
Human trialSTEMI undergoing primary PCI; baseline LVEF ≤40%; without diabetes or heart failureheart10 mg/d40 days
American journal of therapeutics
Dapagliflozin improves left ventricular ejection fraction in humans.
“LVEF was significantly increased.”
Human trial6 monthsn = 25
Cardiology research
Dapagliflozin increases left ventricular ejection fraction in humans.
“Both cohorts demonstrated significant within-group improvements in LVEF, LV volumes, and GLS, with greater remodeling benefits observed in the dapagliflozin arm.”
Human trialsix monthsn = 200
Journal of the Saudi Heart Association
Dapagliflozin improves left ventricular ejection fraction in humans (heart failure with preserved ejection fraction) (p < 0.05).
“At 12-month follow-up, the dapagliflozin group exhibited significant increases in left ventricular ejection fraction”
Human trialheart failure with preserved ejection fraction12 monthsfemalesn = 150
Experimental gerontology
Dapagliflozin is linked with better left ventricular ejection fraction in humans (acute heart failure) (48.36% ± 4.88% vs. 43.85% ± 4.90%).
“left ventricular ejection fraction (48.36% ± 4.88% vs. 43.85% ± 4.90%, P = 0.002)”
Humansacute heart failure10 mg once daily6 months
Frontiers in pharmacology
Dapagliflozin was not clearly linked with left ventricular ejection fraction in humans (perioperative use before mitral valve replacement, compared with control group).
“there were no significant differences in the percentage changes in pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF), right ventricular function (TAPSE)”
Humansperioperative use before mitral valve replacement, compared with control groupleft ventriclen = 196
Frontiers in cardiovascular medicine
Dapagliflozin is linked with better left ventricular ejection fraction in humans (real-world HFrEF patients) (from 29.2% to 34.3% (P < .001)).
“LVEF improved from 29.2% to 34.3% (P < .001)”
Humansreal-world HFrEF patients15.3 ± 8.3 monthsn = 155
Impact of Dapagliflozin on Heart Failure with Reduced Ejection Fraction: A Real-World Study
Journal of clinical pharmacology
All 11Fewer
NT-proBNP
downin humans6no changein humans1upin humans1
8 studies
NT-proBNP
downin humans6no changein humans1upin humans1
Dapagliflozin decreases NT-proBNP in humans (Hospitalized acute heart failure; compared with acetazolamide alongside standard care) (−34.2% vs. −25.0%; P = 0.003).
“Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003).”
Human trialHospitalized acute heart failure; compared with acetazolamide alongside standard care10 mg once daily72 hoursn = 108
Acetazolamide eased breathlessness more in acute heart failure
Clinical pharmacology and therapeutics
Dapagliflozin showed no clear effect on NT-proBNP in humans (Stable PAH or CTEPH; compared with placebo) (Interaction p=0.39).
“or NT-proBNP trajectory through week 4 and 12 (mixed model, interaction p=0.39).”
Human trialStable PAH or CTEPH; compared with placebo10 mg daily4 and 12 weeksn = 52
Dapagliflozin did not clearly improve exercise capacity
ESC Congress 2026 abstract
Dapagliflozin increases NT-proBNP in humans (type 2 diabetes without heart failure, on metformin monotherapy at recruitment) (+20% from baseline; p=0.07).
“whereas it increased by 20% in the dapagliflozin group (p=0.07).”
Human trialtype 2 diabetes without heart failure, on metformin monotherapy at recruitmentplasma6 monthsn = 92
ESC Congress 2026 abstract
Dapagliflozin decreases NT-proBNP in humans (-142 pg/mL (95% CI -324 to 41)).
“The estimated intervention-versus-baseline difference was −142 pg/mL (95% CI −324–41) for NT-proBNP, 24.3 m (95% CI −2.8 to 51.5) for 6MWT distance, and 0.4 points (95% CI −4.0 to 4.8) for KCCQ-TSS.”
Human trial12 weeksn = 7
PloS one
Dapagliflozin decreases NT-proBNP in patients with HFrEF combined with T2DM.
“while their fasting plasma glucose, 2-h postprandial glucose, glycosylated hemoglobin, insulin resistance index, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, cardiac troponin I, creatine kinase-MB, N-terminal pro b-type natriuretic peptide, serum creatinine, and blood urea nitrogen were significantly lower”
Human trialin patients with HFrEF combined with T2DM
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety
World journal of diabetes
Dapagliflozin is linked with lower NT-proBNP in humans (28.4% reduction versus 8.7% reduction in controls).
“NT-proBNP levels in the SGLT-2 inhibitor group exhibited a substantial 28.4% reduction”
HumansHFpEF; combined with standard guideline-directed therapy versus standard guideline-directed therapy alone6 monthsn = 58
American journal of translational research
Dapagliflozin is linked with lower NT-proBNP in humans during doxorubicin therapy in breast cancer patients with type 2 diabetes (+57.000 [95% CI +28.302, +85.698]).
“lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001)”
Humansduring doxorubicin therapy in breast cancer patients with type 2 diabetes3 monthsn = 60
BMC cancer
Dapagliflozin is linked with lower NT-proBNP in humans (heart failure with preserved ejection fraction) (p = 0.046 and p = 0.039).
“NT-proBNP and BNP levels showed significantly greater reductions in the dapagliflozin group (p = 0.046 and p = 0.039, respectively).”
Humansheart failure with preserved ejection fractionn = 215
British journal of hospital medicine (London, England : 2005)
Left ventricular ejection fraction
upin humans6upin mice1
7 studies
Left ventricular ejection fraction
upin humans6upin mice1
Dapagliflozin increases left ventricular ejection fraction in humans (patients with sepsis receiving standardized treatment) (Median 60.0% versus 55.0% in controls).
“On the 5th day of treatment, the median LVEF was significantly higher in the intervention group”
Human trialpatients with sepsis receiving standardized treatmentheart10 mg5 days
Zhonghua nei ke za zhi
Dapagliflozin increases left ventricular ejection fraction in humans (non-diabetic patients with AMI after PCI) (52.24% vs 47.66%).
“Group I demonstrated superior cardiac improvement: higher LVEF (52.24 % vs. 47.66 %; p = 0.025)”
Human trialnon-diabetic patients with AMI after PCIleft ventricle6 months
Journal of the Saudi Heart Association
Dapagliflozin improves left ventricular ejection fraction in patients with HFrEF combined with T2DM.
“After treatment, the pancreatic beta-cell function index, left ventricular ejection fraction, and glomerular filtration rate of patients in the study group were significantly higher than control group (P < 0.001)”
Human trialin patients with HFrEF combined with T2DM
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety
World journal of diabetes
Dapagliflozin is linked with better left ventricular ejection fraction in HFrEF and HFpEF patients (+3.2% in HFrEF, +0.9% in HFpEF).
“LVEF increased in HFrEF (+3.2%) and HFpEF (+0.9%).”
Humansin HFrEF and HFpEF patients3 months
Dapagliflozin and ventricular repolarization across heart failure phenotypes
Current medical research and opinion
Dapagliflozin is linked with higher left ventricular ejection fraction in humans (+5.98 ± 7.39% points).
“mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001)”
Humansn = 213
Scientific reports
Dapagliflozin is linked with higher left ventricular ejection fraction in humans (2DE: 36.6±8.8 vs. 34.5±7.7%; 3DE: 37.4±8.7 vs. 34.4±7.9%; p < 0.001).
“After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased”
HumansHeart failure with reduced ejection fraction on guideline-directed therapy; before-and-after comparisonheart10 mg daily6 monthsn = 75
Echocardiography (Mount Kisco, N.Y.)
Dapagliflozin improves left ventricular ejection fraction in mice (experimental myocardial infarction).
“Consistently, echocardiography showed improved left ventricular ejection fraction and reduced ventricular dilation after MI.”
Animalsexperimental myocardial infarctionheart
ESC Congress 2026 abstract
Mortality
downin humans5upin chickens1no changein humans1+40% mortalityRR 0.67
7 studies
Mortality
downin humans5upin chickens1no changein humans1+40% mortalityRR 0.67
Dapagliflozin showed no clear effect on mortality in humans (critically ill patients with acute kidney injury) (-1.9% (95% CI -14.5 to 10.7)).
“Adjusted risk differences were - 1.9% (95% CI -14.5 to 10.7) for death”
Human trialcritically ill patients with acute kidney injury28 daysn = 212
Journal of critical care
Dapagliflozin decreases mortality in humans.
“As expected, absolute risks of the cardiovascular composite endpoint and all-cause mortality were higher among older participants.”
Human trialmedian of 2.4 yearsn = 4,304
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
Journal of general internal medicine
Dapagliflozin is linked with lower mortality in humans after acute myocardial infarction, after matching (P = 0.033).
“At a median follow-up of 211 days, all-cause mortality remained lower in the DAPA group than in the control group after matching (P = 0.033).”
Humansafter acute myocardial infarction, after matchingmedian follow-up of 211 daysn = 2,607
European journal of clinical pharmacology
Dapagliflozin decreases mortality in humans (early initiation during hospitalization for acute heart failure versus standard therapy) (RR 0.67, 95% CI 0.52-0.86).
“Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52-0.86)”
Reviewearly initiation during hospitalization for acute heart failure versus standard therapy10 mg once dailyn = 3,507
Biomedicines
Dapagliflozin increases mortality in chickens (40% mortality).
“survival rates declining sharply (40% mortality) in the 2.5 mg/mL group”
Animalswhole embryo1.0-2.5 mg/mL
Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model
Journal of applied toxicology : JAT
Dapagliflozin decreases mortality in humans (HFrEF) (OR: 0.83, 95%CI: 0.69 to 0.98).
“Dapagliflozin+triple therapy (SUCRA: 76.8%; OR: 0.83, 95%CI: 0.69 to 0.98) and ARNI+BB+MRA (SUCRA: 76.6%; OR: 0.83, 95%CI: 0.75 to 0.92) demonstrated significant reductions in all-cause mortality.”
ReviewHFrEF
Frontiers in endocrinology
Dapagliflozin decreases mortality in HFrEF (DAPA-HF trial).
“only 2 reduced mortality (sacubitril/valsartan in the PARADIGM-HF trial and dapagliflozin in the DAPA-HF trial)”
Reviewin HFrEF (DAPA-HF trial)
Journal of the American College of Cardiology
Proteinuria
downin humans4no changein humans1
5 studies
Proteinuria
downin humans4no changein humans1
Dapagliflozin decreases proteinuria in humans (compared with placebo).
“Dapagliflozin significantly reduced proteinuria compared with placebo (P = .012) without significantly affecting eGFR.”
Human trialcompared with placebo10 mg daily12 months
Clinical kidney journal
Dapagliflozin decreases proteinuria in humans (chronic kidney disease).
“proteinuria was notably reduced in most patients, indicating a positive renal effect.”
Human trialchronic kidney disease12 monthsn = 12
Journal of diabetes and its complications
Dapagliflozin showed no clear effect on proteinuria in non-diabetic patients with chronic kidney disease, vs placebo (0·9% difference vs placebo (95% CI -16·6 to 22·1)).
“6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes”
Human trialin non-diabetic patients with chronic kidney disease, vs placebo10 mg per day6 weeksn = 53
The lancet. Diabetes & endocrinology
Dapagliflozin is linked with lower proteinuria in humans (glomerular disease patients compared with historical controls) (proteinuria fell 51.9% vs 22.2% in historical cohort; adjusted GMR 0.684).
“Proteinuria fell by 51.9% under dapagliflozin and by 22.2% in the historical cohort; the adjusted geometric mean ratio (GMR) was 0.684 (95% CI 0.534–0.877; p = 0.003).”
Humansglomerular disease patients compared with historical controls
Preprints.orgPreprint
Dapagliflozin is linked with lower proteinuria in humans (compared with matched controls not receiving SGLT2 inhibitors) (median change -157 vs -12 mg/day; Hodges-Lehmann -171 mg/day (95% CI -310 to -32)).
“Proteinuria decreased more in the dapagliflozin group than in controls”
Humanscompared with matched controls not receiving SGLT2 inhibitorskidney10 mg/day12 monthsn = 30
Acta diabetologica
Hepatic steatosis
downin humans3upin chickens1
4 studies
Hepatic steatosis
downin humans3upin chickens1
Dapagliflozin decreases hepatic steatosis in humans (MASLD; compared with aspirin 100 mg once daily) (CAP 260.35 ± 20.78 vs 271.48 ± 12.58 dB/m; p = 0.005).
“Dapagliflozin significantly improved hepatic steatosis, reflected by lower CAP values compared to aspirin”
Human trialMASLD; compared with aspirin 100 mg once dailyliver10 mg once daily6 monthsn = 80
Naunyn-Schmiedeberg's archives of pharmacology
Dapagliflozin decreases hepatic steatosis in T2DM patients with MASLD (-71.02 dB/m).
“Significant reductions were observed in hepatic steatosis (CAP: 316.7 to 245.7 dB/m; mean change - 71.02 dB/m, 95% CI: -63.4 to - 78.6; p < 0.001)”
Human trialin T2DM patients with MASLDliver10 mg daily12 monthsn = 50
Diabetes research and clinical practice
Dapagliflozin is linked with lower hepatic steatosis in humans (MASLD; added to standard of care) (CAP 310.2 to 287.0 dB/m).
“CAP decreased from 314.7 to 278.7 dB /m with saroglitazar and from 310.2 to 287.0 dB /m with dapagliflozin”
HumansMASLD; added to standard of careliver10 mg once daily25 weeksn = 27
Endocrinology, diabetes & metabolism
Dapagliflozin induces hepatic steatosis in chickens.
“Histological examination demonstrated hepatic steatosis, pulmonary emphysema, and cardiac inflammation, alongside neural apoptosis and vascular abnormalities.”
Animalsliver1.0-2.5 mg/mL
Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model
Journal of applied toxicology : JAT
Blood pressure
downin humans2no changein humans1downin mice1
4 studies
Blood pressure
downin humans2no changein humans1downin mice1
Dapagliflozin showed no clear effect on blood pressure in humans (vs placebo).
“changes in systolic and diastolic blood pressure and concentrations of neurohormonal biomarkers did not differ significantly between dapagliflozin and placebo treatment”
Human trialvs placebo10 mg per day6 weeksn = 53
The lancet. Diabetes & endocrinology
Dapagliflozin decreases blood pressure in patients with hypertension and concomitant T2D, CKD, or HF.
“synthesizes the current clinical evidence regarding the antihypertensive effects of dapagliflozin”
Reviewin patients with hypertension and concomitant T2D, CKD, or HF
Efficacy and mechanistic insights of dapagliflozin in hypertension management
Clinical and experimental hypertension (New York, N.Y. : 1993)
Dapagliflozin decreases blood pressure in mice.
“DAPA significantly reduced both systolic blood pressure (SBP) and diastolic blood pressure (DBP) in mice”
Animalssingle dosemales
Frontiers in endocrinology
Dapagliflozin decreases blood pressure in humans (type 2 diabetes mellitus).
“Dapagliflozin also lowers blood pressure due to its natriuresis effect.”
Reviewtype 2 diabetes mellitus
Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
Cureus
Cognitive function
upin humans1no changein humans1upin mice1upin reviews1
4 studies
Cognitive function
upin humans1no changein humans1upin mice1upin reviews1
Dapagliflozin improves cognitive function in humans (type 2 diabetes mellitus and mild cognitive impairment).
“After 36 weeks, the dapagliflozin group demonstrated significant improvements in MoCA and MMSE scores compared to the control group.”
Human trialtype 2 diabetes mellitus and mild cognitive impairment36 weeks
European journal of pharmacology
Dapagliflozin showed no clear effect on cognitive function in humans (head-to-head comparison with liraglutide).
“Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not.”
Human trialhead-to-head comparison with liraglutide16 weeksn = 36
Diabetes care
Dapagliflozin improves cognitive function in experimental models.
“We summarize preclinical evidence suggesting that dapagliflozin can improve cognitive performance and modulate pathways such as AMPK-mTOR”
Reviewin experimental models
Frontiers in pharmacology
Dapagliflozin improves cognitive function in mice (HFD/STZ-induced T2DM mice).
“dapagliflozin could significantly reduce fasting blood glucose levels, alleviate weight loss, and improve cognitive function performance in behavioral tests”
AnimalsHFD/STZ-induced T2DM mice
Toxicology and applied pharmacology
Skeletal muscle mass
downin humans2no changein humans1downin rats1
4 studies
Skeletal muscle mass
downin humans2no changein humans1downin rats1
Dapagliflozin decreases skeletal muscle mass in humans.
“ASM / height2 decreased from 6.72 ± 0.87 to 6.62 ± 0.87 kg/m2 (P = 0.002), whereas ASM/weight did not change (29.0 ± 4.0 to 29.1 ± 3.9%, P = 0.33).”
Human trial4 weeksn = 36
Journal of diabetes investigation
Dapagliflozin showed no clear effect on skeletal muscle mass in humans (compared with non-SGLT2i medicines).
“The absolute change in soft lean mass and skeletal muscle mass was not significantly different between groups.”
Human trialcompared with non-SGLT2i medicinesskeletal muscle5 mg/daysix monthsn = 50
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Journal of atherosclerosis and thrombosis
Dapagliflozin is linked with lower skeletal muscle mass in humans (over approximately six months, in older adults with type 2 diabetes) (skeletal muscle mass index 11.68 ± 1.01 to 11.38 ± 0.88 kg/m2, p = 0.039).
“While dapagliflozin was associated with slight muscle mass loss, empagliflozin preserved muscle.”
Humansover approximately six months, in older adults with type 2 diabetesskeletal muscleapproximately six monthsn = 22
Endocrine
Dapagliflozin decreases skeletal muscle mass in high-fat diet and streptozotocin-induced diabetic rats.
“DAPA alone administration led to a decrease in skeletal muscle mass, whereas RT significantly increased skeletal muscle mass”
Animalsin high-fat diet and streptozotocin-induced diabetic ratsskeletal musclesix weeksmales
Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats
Diabetology & metabolic syndrome
All 447Fewer
What is dapagliflozin linked with?
78Studies link dapagliflozin with 78 measures, among them genital infections, dementia and hypoglycemia.
Genital infections
upin humans3
3 studies
Genital infections
upin humans3
Dapagliflozin raises the risk of genital infections in humans (Patients with diabetes mellitus undergoing TAVR).
“Genital infections were more frequent with dapagliflozin in patients with DM”
Human trialPatients with diabetes mellitus undergoing TAVR12 monthsn = 537
Valve trial found benefit in patients with diabetes and heart failure
Cardiovascular diabetology
Dapagliflozin raises the risk of genital infections in humans (dapagliflozin vs placebo, added to open-label metformin) (3.3% vs 0%).
“events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%”
Human trialdapagliflozin vs placebo, added to open-label metformin10 mg/d24 wk
The Journal of clinical endocrinology and metabolism
Dapagliflozin raises the risk of genital infections in humans (type 2 diabetes).
“Patients in older adults with diabetes took a higher risk of genital infection and renal impairment or failure after treatment of dapagliflozin.”
Reviewtype 2 diabetes
Expert opinion on drug safety
Dementia
downin humans2downin reviews1HR 0.75
3 studies
Dementia
downin humans2downin reviews1HR 0.75
Dapagliflozin is linked with a lower risk of dementia in humans (compared with DPP-4 inhibitors) (aHR 0.67 (95% CI 0.53-0.84)).
“dapagliflozin exhibited the lowest risk (aHR 0.67 [95% CI 0.53-0.84])”
Humanscompared with DPP-4 inhibitorsmean follow-up 2.80 years
Diabetes care
Dapagliflozin lowers the risk of dementia in humans (network meta-analysis versus other antidiabetic medications or placebo) (HR 0.75, 95% CrI 0.59–0.98).
“Dapagliflozin (HR = 0.75, 95% CrI: 0.59, 0.98), and Empagliflozin (HR = 0.69, 95% CrI: 0.55, 0.85) significantly reduced the risk of dementia onset.”
Reviewnetwork meta-analysis versus other antidiabetic medications or placebo
Frontiers in endocrinology
Dapagliflozin lowers the risk of dementia in observational studies.
“distinguishing observational studies that suggest lower dementia risk from randomized clinical evidence”
Reviewin observational studies
Frontiers in pharmacology
Hypoglycemia
upin humans1downin humans1downin silico1RR 2.32
3 studies
Hypoglycemia
upin humans1downin humans1downin silico1RR 2.32
Dapagliflozin raises the risk of hypoglycemia in patients with type 2 diabetes on combination antihypertensive therapy (RR 2.32 (95% CI 1.11 to 4.82)).
“The risk of hypoglycemia was higher in the dapagliflozin group (RR: 2.32; 95% CI 1.11; 4.82; p = 0.024).”
Reviewin patients with type 2 diabetes on combination antihypertensive therapyn = 27,486
ENDO 2025 abstract
Dapagliflozin lowers the risk of hypoglycemia in humans (type 2 diabetes).
“treatment with dapagliflozin reduced the risk of hypoglycemia”
Reviewtype 2 diabetes
Expert opinion on drug safety
Dapagliflozin lowers the risk of hypoglycemia in silico (simulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model) (lower incidence).
“dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events”
In silicosimulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model40 years
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
PloS one
Hospitalization for heart failure
downin humans2RR 0.57–0.75
2 studies
Hospitalization for heart failure
downin humans2RR 0.57–0.75
Dapagliflozin lowers the risk of hospitalization for heart failure in humans (Prediabetes and heart failure; compared with placebo) (RR 0.75, 95% CI 0.58–0.98, p = 0.036).
“SGLT-2 inhibitors reduced hospitalization for heart failure compared with placebo, including dapagliflozin (RR 0.75, 95% CI 0.58–0.98, p = 0.036)”
ReviewPrediabetes and heart failure; compared with placebo
Medical sciences (Basel, Switzerland)
Dapagliflozin lowers the risk of hospitalization for heart failure in humans (Heart failure with mildly reduced or preserved ejection fraction; compared with exenatide) (RR 0.57, 95% CI 0.36-0.91).
“dapagliflozin (RR 0.57, 95% CI 0.36-0.91), empagliflozin (RR 0.54, 95% CI 0.34-0.86), and semaglutide (RR 0.43, 95% CI 0.20-0.91) were related to decreased risk of HF hospitalization.”
ReviewHeart failure with mildly reduced or preserved ejection fraction; compared with exenatide
Drugs
Urinary tract infection
downin humans1upin humans1RR 0.52
2 studies
Urinary tract infection
downin humans1upin humans1RR 0.52
Dapagliflozin is associated with urinary tract infection in a patient with heart failure.
“developed a urinary tract infection and subsequent septic shock following the initiation of dapagliflozin”
Humansin a patient with heart failure2 months before presentationfemales
The Journal of international medical research
Dapagliflozin lowers the risk of urinary tract infection in humans (early initiation during hospitalization for acute heart failure versus standard therapy) (RR 0.52, 95% CI 0.35-0.76).
“Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52-0.86) and urinary tract infections (RR 0.52, 95% CI 0.35-0.76)”
Reviewearly initiation during hospitalization for acute heart failure versus standard therapy10 mg once dailyn = 3,507
Biomedicines
Cardiovascular death
upin humans1downin humans1+4.6% patients
2 studies
Cardiovascular death
upin humans1downin humans1+4.6% patients
Dapagliflozin lowers the risk of cardiovascular death in humans (joint frailty model) (hazard ratio 0.81 (95% CI 0.67-0.98)).
“for cardiovascular death, the hazard ratio was 0.81 (95% CI, 0.67-0.98), P=0.0282”
Human trialjoint frailty model
Circulation
Dapagliflozin is associated with cardiovascular death in humans (4.6% of patients).
“Cardiovascular death was observed in 4.6% of patients”
Humans
Scientific reports
Sarcopenia
upin humans2
2 studies
Sarcopenia
upin humans2
Dapagliflozin is linked with a higher risk of sarcopenia in humans.
“a risk of sarcopenia with Dapagliflozin use”
Humans
Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study
Expert opinion on drug safety
Dapagliflozin is associated with sarcopenia in humans after oral antidiabetes drugs, including dapagliflozin, were initiated.
“She also lost substantial bodyweight and developed sarcopenia.”
Humansafter oral antidiabetes drugs, including dapagliflozin, were initiatedfemales
Journal of diabetes investigation
Mortality
downin humans1downin silico1
2 studies
Mortality
downin humans1downin silico1
Dapagliflozin lowers the risk of mortality in humans.
“Similar to the primary composite outcome, dapagliflozin reduced the incidence of the kidney composite endpoint, cardiovascular composite endpoint, and all-cause mortality across all FI categories.”
Human trialn = 4,303
The journals of gerontology. Series A, Biological sciences and medical sciences
Dapagliflozin lowers the risk of mortality in silico (simulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model) (lower incidence).
“dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events”
In silicosimulated treatment-naive Chinese patients with type 2 diabetes, Cardiff Diabetes Model40 years
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
PloS one
Contrast-induced acute kidney injury
downin humans1OR 0.23
1 study
Contrast-induced acute kidney injury
downin humans1OR 0.23
Dapagliflozin lowers the risk of contrast-induced acute kidney injury in humans (OR 0.23, 95% CI 0.09–0.59).
“The incidence was significantly lower in the dapagliflozin group than in the placebo group (6/161 [3.7%] vs. 23/161 [14.3%]; odds ratio [OR], 0.23; 95% confidence interval, 0.09–0.59; p = 0.001 by Fisher’s exact test).”
Human trialbeginning 3 days before CCTA and continuing until completion of the 72-h post-CCTA follow-upn = 322
Cardiorenal medicine
Dapagliflozin lowers the risk of contrast-induced acute kidney injury in humans (diabetic patients scheduled for CCTA) (6/161 [3.7%] vs. 23/161 [14.3%]).
“CI-AKI occurred in 29 patients overall (9.0%), with a significantly lower incidence in the dapagliflozin group than in the placebo group (6/161 [3.7%] vs. 23/161 [14.3%]; odds ratio, 0.23”
Human trialdiabetic patients scheduled for CCTA10 mg once dailybeginning 3 days before CCTA through 72-h post-CCTAn = 322
Cardiorenal medicine
Higher E/e' quartile
downin humans1OR 0.325
1 study
Higher E/e' quartile
downin humans1OR 0.325
Dapagliflozin lowers the risk of higher E/e' quartile in humans (OR = 0.325, 95% CI: 0.152–0.692).
“Finally, treatment with Dapagliflozin reduces by 67% the chance of being in a higher quartile of E/e’ (OR = 0.325, 95% CI: 0.152–0.692, p = 0.003) (Supplementary Table, Primary analysis).”
Human trial12 weeksn = 98
Cardiovascular diabetology
Dapagliflozin lowers the risk of higher E/e' quartile in humans (type 2 diabetes) (OR 0.325, 95% CI 0.147-0.715).
“Dapagliflozin treatment was associated with a 67% lower likelihood of being in a higher E/e' quartile (OR 0.325; 95% CI 0.147-0.715; p = 0.005).”
Human trialtype 2 diabetes10 mg daily vs glibenclamide 5 mg12 weeksn = 96
Cardiovascular diabetology
Sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes
downin humans1HR 0.5
1 study
Sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes
downin humans1HR 0.5
Dapagliflozin lowers the risk of sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes in humans.
“Compared with placebo, dapagliflozin reduced the risk of primary composite endpoint across all categories of FI with HRs of 0.50 (95% CI, 0.33–0.76), 0.62 (95% CI, 0.45–0.85), and 0.64 (95% CI, 0.49–0.83) in not-to-mildly, moderately, and severely frail categories, respectively.”
Human trialn = 4,303
The journals of gerontology. Series A, Biological sciences and medical sciences
Dapagliflozin lowers the risk of sustained eGFR decline, ESKD, or death from kidney or cardiovascular causes in patients with chronic kidney disease across frailty levels (HR 0.50 (95% CI 0.33-0.76), 0.62 (0.45-0.85), and 0.64 (0.49-0.83) across FI categories).
“Dapagliflozin reduced the risk of the primary composite endpoint across all FI categories”
Human trialin patients with chronic kidney disease across frailty levels10 mg/day
The journals of gerontology. Series A, Biological sciences and medical sciences
Worsening heart failure event or cardiovascular death
downin humans1HR 0.74–0.82
1 study
Worsening heart failure event or cardiovascular death
downin humans1HR 0.74–0.82
Dapagliflozin lowers the risk of worsening heart failure event or cardiovascular death in humans (HR 0.82, 95% CI 0.73–0.92).
“In the overall trial, the HR for the primary composite end point with dapagliflozin compared with placebo was 0.82 (95% CI, 0.73–0.92”
Human trialmedian follow-up of 2.3 yearsn = 6,263
Circulation
Dapagliflozin lowers the risk of worsening heart failure event or cardiovascular death in humans (FI class 3 (most frail)) (HR 0.74, 95% CI 0.61-0.91).
“The effect of dapagliflozin (as a hazard ratio) on the primary end point from FI class 1 to 3 was 0.85 (95% CI, 0.68-1.06), 0.89 (0.74-1.08), and 0.74 (0.61-0.91), respectively”
Human trialFI class 3 (most frail)
Circulation
All-cause death or worsening heart failure
downin humans1HR 0.53
1 study
All-cause death or worsening heart failure
downin humans1HR 0.53
Dapagliflozin lowers the risk of all-cause death or worsening heart failure in humans (Frail patients after transcatheter aortic valve implantation) (HR 0.53, 95% CI 0.36–0.77).
“Dapagliflozin was associated with a lower risk of the primary end point in patients who were frail (HR, 0.53 [95% CI, 0.36-0.77])”
Human trialFrail patients after transcatheter aortic valve implantation12 months
Dapagliflozin may help frail patients more after valve replacement
Journal of the American Heart Association
Composite kidney outcomes
downin humans1RR 0.71
1 study
Composite kidney outcomes
downin humans1RR 0.71
Dapagliflozin lowers the risk of composite kidney outcomes in humans (compared with semaglutide) (RR 0.71, 95% CI 0.53–0.94).
“Dapagliflozin was associated with a lower risk of the composite kidney outcome than semaglutide (RR 0.71, 95% CI: 0.53-0.94)”
Human trialcompared with semaglutide
Diabetes, obesity & metabolism
Genitourinary infections
upin humans1
1 study
Genitourinary infections
upin humans1
Dapagliflozin raises the risk of genitourinary infections in humans.
“although genitourinary infections were more frequent with dapagliflozin”
Human trial10 mg once daily1 year
European journal of heart failure
All 78Fewer
Has dapagliflozin been tested in people?
124 of 406 about agingYes: 107 trials and 135 observational studies in people have been published, and 391 trials are registered.
About aging
Validation & Intervention Testing for Aging, Longevity and Healthspan
Phase 2Not yet recruiting
Anti-Diabetic Medications to Fight PD and LBD
Phase 4Completed
Status unknown
Phase 3Active, not recruiting
Dapagliflozin for Long COVID Syndrome
Phase 3Not yet recruiting
Phase 2Completed
All 40Fewer
Latest change Prostatic neoplasm: Phase 1 → Phase 2Oct 29, 2026
Approved
Nov 11, 2012Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure, controlled type 2 diabetes mellitus
Jan 8, 2014Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Nov 9, 2015Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure
Mar 24, 2023Diabetes Mellitus, Type 2, Heart Failure, Systolic, Heart Failure, Renal Insufficiency, Chronic, Chronic Kidney Disease, chronic heart failure with reduced ejection fraction
Repurposing
Phase 4Completed9 trials
Phase 4Results posted5 trials
Phase 4Completed8 trials
Phase 4Results posted38 trials
Phase 4Results posted1 trial
Phase 4Completed6 trials
40 of 117Fewer
Every condition in trials
TYPE2 diabetes
Phase 4Status unknown3 trials
Motor Activity
Phase 4Results posted2 trials
Diabetic nephropathy type 2
Phase 4Completed1 trial
MASH metabolic dysfunction associated steatohepatitis
Phase 4Recruiting1 trial
Autosomal dominant polycystic kidney
Phase 3Recruiting1 trial
Health condition 1: E119- type 2 diabetes mellitus without complications
Phase 3Recruiting1 trial
All 19Fewer
Readouts due
- Dec 10, 2026
- Dec 31, 2026
- Feb 18, 2027
- Apr 16, 2027
- May 31, 2027
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Phase 4Active, not recruiting
- Jun 2027
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Phase 2Not yet recruiting
All 11Fewer
Stopped
NCT02608905TerminatedType 2 diabetes
Due to difficulty with enrollment of subjects
NCT03152084TerminatedType 2 diabetes
Poor recruitment.
NCT03344341TerminatedType 2 diabetes
Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.
NCT03660683TerminatedType 2 diabetes
Sponsor did not want to continue funding the study
NCT05139914TerminatedType 2 diabetes
The study was halted early because of the inability to enroll participants.
NCT04330079TerminatedPrediabetic state
Slow enrollment. (Difficulty in selecting subjects)
All 11Fewer
Who is developing dapagliflozin?
3 companies: AstraZeneca, Emerald Clinical and THPharm.
Trial sponsors
Company106 trialsPhase 4107,896 people
Company4 trialsPhase 4344 people
Company1 trialPhase 4150 people
Company1 trialPhase 417 people
Company6 trialsPhase 3696 people
Company3 trialsPhase 3300 people
Company2 trialsPhase 3323 people
Company2 trialsPhase 3273 people
Funding
9 grants since 2019National Institute of Diabetes and Digestive and Kidney Diseases$2.3MOffice of the President, University of California$2.4MSão Paulo Research Foundation
Dapagliflozin in Active Lupus Nephritis: A Pilot and Feasibility Randomized Trial
National Institute of Diabetes and Digestive and Kidney DiseasesBrigham and Women's Hospital$365K2026–2028
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Colorado, Denver$655K2023–2028
Pilot trial of SGLT2 inhibitor dapagliflozin for stage Ia lung adenocarcinoma
Office of the President, University of CaliforniaUniversity of California Los Angeles$1.2M2025
Pilot trial of SGLT2 inhibitor dapagliflozin for stage Ia lung adenocarcinoma
Office of the President, University of CaliforniaUniversity of California Los Angeles$1.2M2025–2028
São Paulo Research FoundationUniversidade Estadual De Campinas2025–2027
São Paulo Research FoundationFundação Faculdade de Medicina2025–2027
Health and Medical Research FundThe University of Hong KongHK$1.4M2024
Japan Society for the Promotion of ScienceKyoto Pharmaceutical University¥4.7M2023–2026
Swiss National Science FoundationUniversity of BernCHF 265K2019–2023
How this record changed
Summary rewritten as its findings changed.
As it read before
Dapagliflozin improves healthspan in a fly study and reduces heart failure events in human trials. Independent labs reproduce reduced oxidative stress in mice, but HbA1c results differ across human trials. Aging-related trials are registered; across all uses, some trials ended over a year ago without posted results, and papers declare ties to developer and funder AstraZeneca.
Summary rewritten as its findings changed.
As it read before
Dapagliflozin reduces senescence in mice across independent labs and improves healthspan in a fly study; a human trial shows no clear senescence effect. Human trials report fewer heart failure events and reduced chronic kidney disease, but a trial shows no clear cardiovascular mortality effect. Some human papers declare ties to developer AstraZeneca.
Summary rewritten as its findings changed.
As it read before
Dapagliflozin reduces cellular senescence in mice across independent labs, but a human trial shows no clear effect on senescence. Human trials report lower mortality and fewer heart failure events. There are 124 aging-related trials; across all uses, 103 trials ended over a year ago without posted results or citing papers. AstraZeneca funds studies, and developers sponsor trials.
Summary rewritten as its findings changed.
As it read before
Independent labs reproduce reduced cellular senescence in mice with dapagliflozin, while a human trial reports no change; one group reports improved fly healthspan. Human trials report fewer heart failure events; a trial finds no cardiovascular mortality change. Developers sponsor 161 trials; 63 trials concern aging, and 100 across all uses ended over a year ago without posted results or citing papers.
Summary rewritten as its findings changed.
As it read before
Dapagliflozin reduces senescence in human cells across independent labs; human trials report fewer heart-failure events and slower CKD progression, while fly healthspan improves but aged-killifish lifespan does not. HbA1c results differ; 41 registered trials concern aging, while 100 across uses ended over a year ago without posted results. AstraZeneca funds work and has author ties; developer companies sponsor 158 trials across uses.